Conference Coverage

VIDEO: Simple skin finding differentiates diffuse scleroderma from limited disease


 

EXPERT ANALYSIS FROM THE ANNUAL PERSPECTIVES IN RHEUMATIC DISEASES

References

LAS VEGAS – Scleroderma treatment is evolving quickly.

Newer classification criteria from the American College of Rheumatology and the European League Against Rheumatism are helping diagnose and treat the disease earlier, and ongoing investigations are defining the proper roles of mycophenolate mofetil, cyclophosphamide, stem cell transplants, and other treatments in the disease. Meanwhile, the Food and Drug Administration has granted Breakthrough Therapy Designation status to tocilizumab for its development as a potential treatment for scleroderma.

In an interview at the annual Perspectives in Rheumatic Diseases held by Global Academy for Medical Education, Dr. Daniel Furst, the Carl M. Pearson Professor in Rheumatology at the University of California, Los Angeles, gave a quick review of those and other recent developments and shared a few treatment pearls, including how he uses a simple skin finding to differentiate diffuse from limited disease.

Global Academy for Medical Education and this news organization are owned by the same parent company.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

aotto@frontlinemedcom.com

Recommended Reading

VIDEO: Assessment tool rapidly screens lupus cognition
MDedge Family Medicine
Pregnancy outcomes better than expected in SLE
MDedge Family Medicine
Early nonadherence ups emergency care, hospitalization for lupus
MDedge Family Medicine
EULAR: Updated scleroderma guidance focuses on new treatments, approaches
MDedge Family Medicine
Counseling key to guiding rheumatic disease treatment during pregnancy
MDedge Family Medicine
EULAR: Panel targets six rheumatic disease comorbidities
MDedge Family Medicine
New IPF guidelines limit treatment choices
MDedge Family Medicine
First-line ambrisentan plus tadalafil halved PAH events
MDedge Family Medicine
Tabalumab development for lupus stops because of mixed phase III results
MDedge Family Medicine
VIDEO: Don’t rely on ANCA to diagnose primary vasculitis
MDedge Family Medicine